Özge Vural
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Özge Vural has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Arzu Okur
Gazi University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Türkiye
5 shared publications - Faruk Güçlü Pınarlı
Gazi University
5 shared publications - İbRahim Eker
Afyonkarahisar Health Sciences University Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Afyonkarahisar, Türkiye
4 shared publications Arzu Okur
Gazi Univ, Dept Pediat Hematol & Oncol, Fac Med, TR-06500 Ankara, Turkiye
3 shared publications- Hilal Susam Şen
Hacettepe University Faculty of Medicine
3 shared publications - Büşra Topuz Türkcan
Gazi University
2 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Evaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Open AccessEvaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- 20 August 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-10
Evaluation of sleep disturbances in pediatric cancer patients and sleep quality in their caregivers
Cancer remains one of the leading causes of mortality among children worldwide. Both the disease itself and its treatment contribute to significant sleep-related issues. Pediatric cancer patients and survivors commonly experience sleep disturbances, including insomnia, excessive daytime sleepiness, prolonged sleep latency, reduced sleep duration, and poor overall sleep quality. The primary objective of this study was to assess the prevalence and characteristics of sleep disturbances in pediatric cancer patients and to compare these findings with those observed in children with non-oncologic conditions managed by the same pediatric oncology clinic. A secondary aim was to evaluate whether sleep disturbances in children affect the sleep quality of their caregivers. The study included 210 children aged 6 to 16 years and their caregivers. Diagnoses included lymphoma, solid tumors, Langerhans cell histiocytosis, neurofibromatosis, lymphadenopathy, and hemangioma. All participants were followed in our outpatient clinic between January 2 and May 25, 2023. Caregivers completed the Pittsburgh Sleep Quality Index (PSQI) to assess their own sleep quality and the Sleep Disturbance Scale for Children (SDSC) to evaluate their child's sleep patterns. The mean SDSC total score was 40.8 ± 8.1, indicating a high prevalence of sleep disturbances among children with cancer, particularly difficulties in initiating and maintaining sleep. The mean caregiver PSQI score was 5.02 ± 3.56. A moderate, statistically significant correlation was found between children's SDSC scores and their caregivers' PSQI scores (r = 0.433, p < 0.001). These findings underscore the importance of routine sleep assessments in pediatric oncology. Early recognition and management of sleep disturbances may enhance treatment adherence, improve therapeutic outcomes, and increase the overall quality of life for both patients and their caregivers.
- 20 August 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-10
Evaluation of sleep disturbances in pediatric cancer patients and sleep quality in their caregivers
Cancer remains one of the leading causes of mortality among children worldwide. Both the disease itself and its treatment contribute to significant sleep-related issues. Pediatric cancer patients and survivors commonly experience sleep disturbances, including insomnia, excessive daytime sleepiness, prolonged sleep latency, reduced sleep duration, and poor overall sleep quality. The primary objective of this study was to assess the prevalence and characteristics of sleep disturbances in pediatric cancer patients and to compare these findings with those observed in children with non-oncologic conditions managed by the same pediatric oncology clinic. A secondary aim was to evaluate whether sleep disturbances in children affect the sleep quality of their caregivers. The study included 210 children aged 6 to 16 years and their caregivers. Diagnoses included lymphoma, solid tumors, Langerhans cell histiocytosis, neurofibromatosis, lymphadenopathy, and hemangioma. All participants were followed in our outpatient clinic between January 2 and May 25, 2023. Caregivers completed the Pittsburgh Sleep Quality Index (PSQI) to assess their own sleep quality and the Sleep Disturbance Scale for Children (SDSC) to evaluate their child's sleep patterns. The mean SDSC total score was 40.8 ± 8.1, indicating a high prevalence of sleep disturbances among children with cancer, particularly difficulties in initiating and maintaining sleep. The mean caregiver PSQI score was 5.02 ± 3.56. A moderate, statistically significant correlation was found between children's SDSC scores and their caregivers' PSQI scores (r = 0.433, p < 0.001). These findings underscore the importance of routine sleep assessments in pediatric oncology. Early recognition and management of sleep disturbances may enhance treatment adherence, improve therapeutic outcomes, and increase the overall quality of life for both patients and their caregivers.
- Open Access
- 13 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (2) , 233-234
Positron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia
Cite this article as: Kaya Z, Kirkiz Kayalı S, Topuz Türkcan B, et al. Positron emission tomography imaging and HScore-based diagnosis in two children with malignancy-associated hemophagocytic syndrome: anaplastic large-cell lymphoma and precursor B-acute lymphoblastic leukemia. Turk Arch Pediatr. 2025;60(2):233-234.
- 13 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (2) , 233-234
Open AccessPositron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia
Cite this article as: Kaya Z, Kirkiz Kayalı S, Topuz Türkcan B, et al. Positron emission tomography imaging and HScore-based diagnosis in two children with malignancy-associated hemophagocytic syndrome: anaplastic large-cell lymphoma and precursor B-acute lymphoblastic leukemia. Turk Arch Pediatr. 2025;60(2):233-234.
- 5 September 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (8) , 438-441
Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency
Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70-deficient pediatric patient with PBL.
- 5 September 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (8) , 438-441
Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency
Combined immunodeficiency due to CD70 deficiency is characterized by increased susceptibility to infections, hypogammaglobulinemia, and malignancy. These patients typically present with chronic Epstein Barr virus (EBV) viremia, severe EBV-related hemophagocytic lymphohistiocytosis, lymphoproliferation, and Hodgkin and non-Hodgkin lymphomas. Plasmablastic lymphoma (PBL) is an extremely rare malignancy in all ages and is predominantly seen in male adults with human immunodeficiency virus infection. EBV infection, immunosuppression, solid organ transplantation, and age-related immune deterioration are also suspected causes of PBL. Nevertheless, there is scarce data about its association with primary immunodeficiencies in the literature. Here, we present the first case of a CD70-deficient pediatric patient with PBL.
- 1 January 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (1) , 47-51
Evaluation of Head and Neck Lymphadenopathies in Childhood
- 1 January 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (1) , 47-51
Evaluation of Head and Neck Lymphadenopathies in Childhood
- 15 October 2023
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 14 (suppl3) , 315-318
Evaluation of biopsy performed childhood lymphadenopathies: single center experience
Aim The aim of the study was to evaluate patients who were followed up with lymphadenopathy and underwent biopsy in Afyon Health Sciences University Pediatric Hematology/Oncology Department and to assess the potential correlations between the presence of antibodies against EBV antigens in serum samples and the presence of EBER in lymph node tissues. Methods All cases diagnosed with lymphadenopathy and excisional biopsy performed in the Pediatric Hematology and Oncology Department, between January 2018 to January 2020 were retrospectively evaluated. Medical records (gender, age, medical history, sore throat, fever, cough, history of upper respiratory tract infection, animal contact and travel, duration of symptoms) of patients, as well as their treatment history were examined. Tissue EBER status, serological tests for EBV (EBV VCA IgG, VCA IgM, EBNA IgG, EBNA IgM, and EA IgG) data were recorded from files. Results Our study included 22 patients comprising 10 females (%45.4) and 12 males (%54.5). At the time of the diagnosis, the median age was 8 (range, 2 to 17) years. Five (22.6%) of 22 biopsies were reported to be malignant. Reactive lymphoid hyperplasia was seen in 15 (68.1%) patients. Statistical analysis revealed a significant correlation between anti-VCA IgG serology and the EBER status (P=0.03). Conclusion In conclusion, lymphadenopathy is a common clinical condition in childhood and often develops due to reactive hyperplasia. It was determined that patients with serum EBVVCA IgG positive were also EBER positive in the tissue.
- 15 October 2023
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 14 (suppl3) , 315-318
Evaluation of biopsy performed childhood lymphadenopathies: single center experience
Aim The aim of the study was to evaluate patients who were followed up with lymphadenopathy and underwent biopsy in Afyon Health Sciences University Pediatric Hematology/Oncology Department and to assess the potential correlations between the presence of antibodies against EBV antigens in serum samples and the presence of EBER in lymph node tissues. Methods All cases diagnosed with lymphadenopathy and excisional biopsy performed in the Pediatric Hematology and Oncology Department, between January 2018 to January 2020 were retrospectively evaluated. Medical records (gender, age, medical history, sore throat, fever, cough, history of upper respiratory tract infection, animal contact and travel, duration of symptoms) of patients, as well as their treatment history were examined. Tissue EBER status, serological tests for EBV (EBV VCA IgG, VCA IgM, EBNA IgG, EBNA IgM, and EA IgG) data were recorded from files. Results Our study included 22 patients comprising 10 females (%45.4) and 12 males (%54.5). At the time of the diagnosis, the median age was 8 (range, 2 to 17) years. Five (22.6%) of 22 biopsies were reported to be malignant. Reactive lymphoid hyperplasia was seen in 15 (68.1%) patients. Statistical analysis revealed a significant correlation between anti-VCA IgG serology and the EBER status (P=0.03). Conclusion In conclusion, lymphadenopathy is a common clinical condition in childhood and often develops due to reactive hyperplasia. It was determined that patients with serum EBVVCA IgG positive were also EBER positive in the tissue.
- Open Access
- 30 September 2023
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 13 (5) , 923-927
Evaluation of Neurofibromatosis Type 1 Associated Optic Pathway Gliomas
Background/Aims: Optic pathway gliomas (OPGs) are low-grade gliomas histologically represented by pilocytic astrocytoma (PA) in 90% of cases, can develop from any part of the visual pathways such as optic nerve, chiasm, optic tract, or optic radiations which frequently involve the hypothalamus. OPGs account for 3–5% of childhood central nervous system (CNS) tumors and about 2% of pediatric glial lesions. OPGs are believed to be the most prevalent intracranial tumor in patients with neurofibromatosis type 1 (NF-1) and can occur in 15–20% of NF-1 cases. The aim of this study is to evaluate the clinical features and treatment response in patients diagnosed with optic glioma and NF-1. Methods: All cases diagnosed with OPG and received treatment in the Pediatric Oncology Department, between January 2015 to January 2021 were retrospectively evaluated. Inclusion criteria include children and adolescents with OPG aged between 0 and 18 years. The medical records (gender, age, tumor entity, tumor location) of patients, as well as their treatment history and magnetic resonance imaging (MRI) scans, were examined. The diagnosis of OPG was made clinically and radiologically by the tumor board. The recommendations of the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group were used in the diagnosis and evaluation of treatment response. Patients received intravenous chemotherapy with SIOP LGG 2004 (vincristine- carboplatin) with or without bevacizumab (10 mg/kg, started every 2 weeks), therapy or vinblastine (3 mg/m2, weekly). Results: This study included 27 cases during the study period from January 2015 to January 2021. In this study there were 14 male (51.8 %) and 13 female (48.1 %) patients. The median age was 4.8 (range: 0.5–14.9) years. Biopsy was performed in three patients and the diagnosis was low-grade glioma (pilocytic astrocytoma) for all of them. Chemotherapy was administered to 22 cases in total. Twelve patients received vincristine-carboplatine, 5 patients received vincristine-carboplatin with bevacizumab and 5 patients received vinorelbine. Radiological response was evaluated in all 22 patients at 3 months MRI. No patient had a radiological complete respons, 11 patients (50%) had partial response, 2 patients (9%) presented with a progressive disease, showing an increase in measurements of 35% and 9 patients(40.9%) had stable disease at the 3-month evaluation. Conclusions: Systemic and visual problems play a significant role in the selection of treatment for pediatric patients with optic gliomas. An essential treatment option for improving symptoms and reducing tumor size is systemic chemotherapy. A crucial therapy option for enhancing vision is bevacizumab for the patients with NF-associated OPG.
- 30 September 2023
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 13 (5) , 923-927
Open AccessEvaluation of Neurofibromatosis Type 1 Associated Optic Pathway Gliomas
Background/Aims: Optic pathway gliomas (OPGs) are low-grade gliomas histologically represented by pilocytic astrocytoma (PA) in 90% of cases, can develop from any part of the visual pathways such as optic nerve, chiasm, optic tract, or optic radiations which frequently involve the hypothalamus. OPGs account for 3–5% of childhood central nervous system (CNS) tumors and about 2% of pediatric glial lesions. OPGs are believed to be the most prevalent intracranial tumor in patients with neurofibromatosis type 1 (NF-1) and can occur in 15–20% of NF-1 cases. The aim of this study is to evaluate the clinical features and treatment response in patients diagnosed with optic glioma and NF-1. Methods: All cases diagnosed with OPG and received treatment in the Pediatric Oncology Department, between January 2015 to January 2021 were retrospectively evaluated. Inclusion criteria include children and adolescents with OPG aged between 0 and 18 years. The medical records (gender, age, tumor entity, tumor location) of patients, as well as their treatment history and magnetic resonance imaging (MRI) scans, were examined. The diagnosis of OPG was made clinically and radiologically by the tumor board. The recommendations of the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group were used in the diagnosis and evaluation of treatment response. Patients received intravenous chemotherapy with SIOP LGG 2004 (vincristine- carboplatin) with or without bevacizumab (10 mg/kg, started every 2 weeks), therapy or vinblastine (3 mg/m2, weekly). Results: This study included 27 cases during the study period from January 2015 to January 2021. In this study there were 14 male (51.8 %) and 13 female (48.1 %) patients. The median age was 4.8 (range: 0.5–14.9) years. Biopsy was performed in three patients and the diagnosis was low-grade glioma (pilocytic astrocytoma) for all of them. Chemotherapy was administered to 22 cases in total. Twelve patients received vincristine-carboplatine, 5 patients received vincristine-carboplatin with bevacizumab and 5 patients received vinorelbine. Radiological response was evaluated in all 22 patients at 3 months MRI. No patient had a radiological complete respons, 11 patients (50%) had partial response, 2 patients (9%) presented with a progressive disease, showing an increase in measurements of 35% and 9 patients(40.9%) had stable disease at the 3-month evaluation. Conclusions: Systemic and visual problems play a significant role in the selection of treatment for pediatric patients with optic gliomas. An essential treatment option for improving symptoms and reducing tumor size is systemic chemotherapy. A crucial therapy option for enhancing vision is bevacizumab for the patients with NF-associated OPG.
- 18 August 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (8) , 1274-1279
Clinical and genetic characteristics of retinoblastoma patients in a single center with four novel RB1 variants
AIM: To assess the clinical and genetic characteristics of children diagnosed with retinoblastoma (RB) at Gazi University Faculty of Medicine’s Department of Pediatric Oncology. METHODS: All cases diagnosed with RB and received treatment and follow-up in the Ophthalmology and Pediatric Oncology Department, October 2016 to May 2021 were evaluated retrospectively. The RB1 gene was analyzed by next-generation sequencing (NGS) technique in DNAs obtained from peripheral blood samples of the patients. RESULTS: This study included 53 cases with 67 RB-affected eyes during the study period. The mean age was 24.6 (median: 18.5, range: 3–151)mo. There were 15 (22.3%) Group D eyes and 39 (58.2%) Group E eyes. The RB1 gene was sequenced by the NGS method in 19 patients. Heterozygous RB1:NM_000321.3: c.54_76del (p.Glu19AlafsTer4) variant was detected in a 15-month-old female with bilateral RB. Heterozygous RB1:NM_000321.3: c.1814+3A>T variant was detected in a 5.5-month-old male with bilateral RB. The intronic RB1:NM_000321.3: c.1332+4A>G variant was detected in patient 14, a 13-month-old male with unilateral RB. The RB1:NM_000321.3: c.575_576del (p.Lys192SerfsTer10) variant was found in an 18-month-old female with an allele frequency of 37%. These variants have not been reported in the literature and mutation databases. CONCLUSION: Four novel variants are described and one of them is found in two different patients. This data is crucial for assessing prognosis. It serves as a guide for estimating the long-term risk of secondary malignancy as well as the short-term risk of developing additional malignancies in the same eye and the other eye.
- 18 August 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (8) , 1274-1279
Clinical and genetic characteristics of retinoblastoma patients in a single center with four novel RB1 variants
AIM: To assess the clinical and genetic characteristics of children diagnosed with retinoblastoma (RB) at Gazi University Faculty of Medicine’s Department of Pediatric Oncology. METHODS: All cases diagnosed with RB and received treatment and follow-up in the Ophthalmology and Pediatric Oncology Department, October 2016 to May 2021 were evaluated retrospectively. The RB1 gene was analyzed by next-generation sequencing (NGS) technique in DNAs obtained from peripheral blood samples of the patients. RESULTS: This study included 53 cases with 67 RB-affected eyes during the study period. The mean age was 24.6 (median: 18.5, range: 3–151)mo. There were 15 (22.3%) Group D eyes and 39 (58.2%) Group E eyes. The RB1 gene was sequenced by the NGS method in 19 patients. Heterozygous RB1:NM_000321.3: c.54_76del (p.Glu19AlafsTer4) variant was detected in a 15-month-old female with bilateral RB. Heterozygous RB1:NM_000321.3: c.1814+3A>T variant was detected in a 5.5-month-old male with bilateral RB. The intronic RB1:NM_000321.3: c.1332+4A>G variant was detected in patient 14, a 13-month-old male with unilateral RB. The RB1:NM_000321.3: c.575_576del (p.Lys192SerfsTer10) variant was found in an 18-month-old female with an allele frequency of 37%. These variants have not been reported in the literature and mutation databases. CONCLUSION: Four novel variants are described and one of them is found in two different patients. This data is crucial for assessing prognosis. It serves as a guide for estimating the long-term risk of secondary malignancy as well as the short-term risk of developing additional malignancies in the same eye and the other eye.
- 13 July 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 24 (3) , 305-313
A NIGHTMARE FOR TRANSPLANT PHYSICIANS: BONE MARROW DONOR CANDIDATES WITHDRAWING FROM THE DONATION PROCESS
OBJECTIVE: Although there have been remarkable developments regarding stem-cell transplantation (HSCT) in Turkey, but the number of people who would like to be stem cell donors is not yet at the desired level. The present study aimed to assess the effect of the training delivered by specialists on the thoughts and decisions of the health employees working in our center on being HSCT donors. MATERIAL AND METHODS: Employees in the health sector who have not received any training in HSCT were included in the study. A half-hour of collective training for all participants was delivered by the General Directorate of Health Services Turkey Stem Cell Coordination Center (TÜRKÖK) on January 11-12, 2018. The present study included 274 health employeeswho attended the training delivered by TÜRKÖK. The pre-testand post-test were applied to determine the socio-demographic characteristics of the participants, their knowledge andattitudes about stem cell transplantation before and after thetraining, and the factors that motivate and prevent them frombeing a donor. RESULTS: Among the 95 participants, who did not think about being a donor before receiving education, the factors that caused them to not want to be a donor the most were their distrust of the health system (16.5%), the worry of causing pain (15.4%), and the thought that being a bone marrow donor had a negative impact on health (13.4%). A statistically significant increase was found in the rate of those who think about becoming a stem cell transplant donor after education (p:,0001), those who think they have enough information about stem cell transplant (p:,0001), those who think they know where to apply to be a stem cell donor (p:,000) those who thought that the society was sufficiently informed about stem cell transplantation (p:,0001). While 67.3% (171 people) of the participants stated that their determination to be a donor would continue until the end of the whole process, 32.7% (83 people) stated that they could stop being a donor. CONCLUSIONS: Our results show that continuing giving such trainings, especially in institutions, will contribute to the increase of the number of stem cell donor volunteers to a sufficient level by raising awareness on the subject and reducing false beliefs in our country.
- 13 July 2023
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 24 (3) , 305-313
A NIGHTMARE FOR TRANSPLANT PHYSICIANS: BONE MARROW DONOR CANDIDATES WITHDRAWING FROM THE DONATION PROCESS
OBJECTIVE: Although there have been remarkable developments regarding stem-cell transplantation (HSCT) in Turkey, but the number of people who would like to be stem cell donors is not yet at the desired level. The present study aimed to assess the effect of the training delivered by specialists on the thoughts and decisions of the health employees working in our center on being HSCT donors. MATERIAL AND METHODS: Employees in the health sector who have not received any training in HSCT were included in the study. A half-hour of collective training for all participants was delivered by the General Directorate of Health Services Turkey Stem Cell Coordination Center (TÜRKÖK) on January 11-12, 2018. The present study included 274 health employeeswho attended the training delivered by TÜRKÖK. The pre-testand post-test were applied to determine the socio-demographic characteristics of the participants, their knowledge andattitudes about stem cell transplantation before and after thetraining, and the factors that motivate and prevent them frombeing a donor. RESULTS: Among the 95 participants, who did not think about being a donor before receiving education, the factors that caused them to not want to be a donor the most were their distrust of the health system (16.5%), the worry of causing pain (15.4%), and the thought that being a bone marrow donor had a negative impact on health (13.4%). A statistically significant increase was found in the rate of those who think about becoming a stem cell transplant donor after education (p:,0001), those who think they have enough information about stem cell transplant (p:,0001), those who think they know where to apply to be a stem cell donor (p:,000) those who thought that the society was sufficiently informed about stem cell transplantation (p:,0001). While 67.3% (171 people) of the participants stated that their determination to be a donor would continue until the end of the whole process, 32.7% (83 people) stated that they could stop being a donor. CONCLUSIONS: Our results show that continuing giving such trainings, especially in institutions, will contribute to the increase of the number of stem cell donor volunteers to a sufficient level by raising awareness on the subject and reducing false beliefs in our country.
- 1 April 2023
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 21 (1) , 92-97
Adölesanlarda Anormal Uterin Kanamaya Hematolog Gözüyle Yaklaşım
- 1 April 2023
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 21 (1) , 92-97
Adölesanlarda Anormal Uterin Kanamaya Hematolog Gözüyle Yaklaşım